Crisaborole Powder CAS 906673-24-3 PDE-4 inhibitors

Boiling point 425.9±55.0 °C(Predicted)
density 1.33±0.1 g/cm3(Predicted)
storage temp. room temp
form powder
pka 7.00±0.20(Predicted)
color white to beige


Product Name: 5-(4-cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole
CAS No.: 906673-24-3
LogP: 1.56828
Molecular Formula: C14H10BNO3
PSA: 62.5
Molecular Weight: 251
Exact Mass: 251.075378
H-bond Acceptor: 4
H-bond Donor: 1
SP3: 0.07
Categories: Inhibitor Drugs

Application & Function

Crisaborole is a phosphodiesterase- 4 (PDE4) inhibitor that was approved by the USFDA for the treatment of mild to moderate atopic dermatitis (AD) in patients aged two years and older. The drug, which was developed by Anacor Pharmaceuticals and later acquired and marketed by Pfizer, is delivered as a 2% ointment, which is applied topically. The unique employment of boron within the chemical structure of the drug is designed to enable selective engagement of PDE4 (an enzyme involved in the conversion of cAMP into AMP, which signals for downstream inflammatory events), effective penetration of the drug through human skin, and rapid clearance to limit systemic circulation